IMR Press / EJGO / Volume 2 / Issue 2 / pii/1981014

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Fibrinolysis in ovarian cancer

Show Less
1 Institute of Obstetrics and Gynecology, University of Padua (Italy)
2 Medical Oncology Division, Regional Hospital of Padua (Italy)
Eur. J. Gynaecol. Oncol. 1981, 2(2), 70–72;
Published: 10 June 1981

Coagulation disorders, including thromboembolic phenomena and disseminated intravascular coagulation are recognised as a complication of neoplastic disease. In the present study the Fibrinogen Degradation Products (F.D.P.) were determined in 26 patients with Advanced Ovarian Cancer (stage III and IV FIGO)(x= 38.1; S.D. = 37.6) and in ten healthy patients considered as controls(x= 2.7; S.D. = 1.3). The significative difference (p < 0.05) between the two groups points in evidence an increasing activation of fibrynolitic processes. The F.D.P. determination has revealed a good correlation (p < 0.001) with the tumor extension as showed by the difference between third stage with large tumor masses (late)(x= 44.5; S.D. = 24.5) and third stage with minimal residual disease after reductive surgery (early)(x= 6.7; S.D. = 5.7).

Ovarian cancer
Coagulation factors
Back to top